Table 1.
Characteristics of the series of patients with breast cancer.
| N | (%) | |
|---|---|---|
| Patients included | 109 | 100 |
| Median age at surgery (Y) | 60 (34–92) | |
| Gender | ||
| Females | 109 | (100) |
| Males | 0 | (0) |
| Histologicial grade (G) | ||
| 1 | 7 | (6.4) |
| 2 | 56 | (51.4) |
| 3 | 46 | (42.2) |
| T 1 stadium | ||
| 1 | 52 | (47.7) |
| 2 | 53 | (48.6) |
| 3 | 4 | (3.7) |
| N 2 stadium | ||
| 0 | 62 | (56.9) |
| 1 | 27 | (24.8) |
| 2 | 11 | (10.1) |
| 3 | 9 | (8.2) |
| M 3 stadium | ||
| 0 | 108 | (99.1) |
| 1 | 1 | (0.9) |
| Relapse occurence | ||
| Loco-regional | 10 | (9.2) |
| Distant metastasis | 33 | (30.3) |
| Histology | ||
| Infiltrating Ductal | 90 | (82.6) |
| Infiltrating Lobular | 10 | (9.2) |
| Medullary | 1 | (0.9) |
| Several types | 8 | (7.3) |
| Molecular subtype | ||
| Luminal A | 60 | (55) |
| Luminal B | 10 | (9.2) |
| HER2 | 24 | (22) |
| TNBC | 15 | (13.8) |
| HER2 4 | ||
| Positive | 26 | (23.9) |
| Negative | 83 | (76.1) |
| PGR 5 | ||
| Positive | 50 | (45.9) |
| Negative | 59 | (54.1) |
| ER 6 | ||
| Positive | 82 | (75.2) |
| Negative | 27 | (24.8) |
1 tumor size; T1 < 20 mm, T2 20–50 mm, T3 > 50 mm, 2 nodal involvement; N0 no cancer cells are seen in loco-regional lymph nodes, N1 cancer has spread to 1–3 axillary lymph nodes and/or internal mammary lymph nodes, N2 cancer has spread to 4–9 axillary lymph nodes or cancer has enlarged the internal mammary lymph nodes, N3 cancer has spread to 10 or more axillary lymph nodes or to clavicular lymph nodes, 3 metastases; M0 no distant spreading, M1 cancer has spread to distant organs, 4 human epidermal growth factor receptor 2 expression; positive when IHC 3+ or IHC 2+ and amplified, 5 progesterone receptor expression; positive > 10%, 6 estrogen receptor expression; positive > 1%.